Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a ...

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

The European Union reached a deal with Pfizer and BioNTech for 300 million additional doses of their COVID-19 vaccine, the ...

And despite the sales slump in the U.S. this past quarter, Pfizer’s Prevnar dynasty still leads in pediatric pneumococcal vaccination worldwide and among conjugated pneumococcal vaccines for adults in ...

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday as both companies submitted ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...

Pfizer has today lifted its full-year profit forecast for the second time in a row as robust demand for its blockbuster heart treatment and blood thinner helped it post third-quarter earnings above ...

Investing.com - Pfizer has raised and narrowed its full-year earnings outlook for a second consecutive quarter, after strong demand for its blood thinner medication helped fuel solid third-quarter ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...